News Releases


2019 | 2018 | 2017 | Archive
Keyword Search
 
DateTitle 
06/25/19New National Event Series "Parkinson's IQ + You" Launches to Educate and Empower Parkinson's Disease Patients and Care Partners
- "Parkinson's IQ + You" events are designed to empower people with Parkinson's and care partners to manage the disease, learn about research participation and connect with local resources - This series of events is presented by The Michael J. Fox Foundation and funded by ACADIA Pharmaceuticals, with additional support from a consortium of biotech and pharmaceutical partners - Events in Atlanta and Southern California are scheduled for fall 2019, with more to follow in 2020. Registration i... 
Printer Friendly Version
06/04/19ACADIA Pharmaceuticals to Present at the Goldman Sachs 40th Annual Global Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)--Jun. 4, 2019-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the Goldman Sachs 40th Annual Global Healthcare Conference on Tuesday, June 11, 2019 at 1:20 p.m. Pacific Time in Rancho Palos Verdes, California. ... 
Printer Friendly Version
05/18/19ACADIA Pharmaceuticals to Present Phase 2 CLARITY Results for Pimavanserin as an Adjunctive Treatment in Major Depressive Disorder at the 2019 American Psychiatric Association Annual Meeting
SAN DIEGO--(BUSINESS WIRE)--May 18, 2019-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced it will present data from its Phase 2 CLARITY study, which evaluated the efficacy, safety, and tolerability of pimavanserin as an adjunctive treatment for major depressive disorder (MDD)... 
Printer Friendly Version
05/07/19ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch Health Care Conference 2019
SAN DIEGO--(BUSINESS WIRE)--May 7, 2019-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the Bank of America Merrill Lynch Health Care Conference 2019 on Tuesday, May 14, 2019 at 10:40 a.m. Pacific Time in Las Vegas. A live webcast of ... 
Printer Friendly Version
05/01/19ACADIA Pharmaceuticals Reports First Quarter 2019 Financial Results
- 1Q19 Net Sales Grew to $63.0 Million, a 29% Increase Over 1Q18 - Updated 2019 Net Sales Guidance to $280 Million to $300 Million - Completed Enrollment in Two Late-Stage Adjunctive Schizophrenia Studies with Pimavanserin SAN DIEGO--(BUSINESS WIRE)--May 1, 2019-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medica... 
Printer Friendly Version
04/25/19ACADIA Pharmaceuticals Initiates Phase 3 CLARITY Program with Pimavanserin as Adjunctive Treatment for Major Depressive Disorder
SAN DIEGO--(BUSINESS WIRE)--Apr. 25, 2019-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced the initiation of the Phase 3 CLARITY-2 study and plans to initiate the Phase 3 CLARITY-3 study in the upcoming months. These studies will evaluate the efficacy and safety of ... 
Printer Friendly Version
04/17/19ACADIA Pharmaceuticals to Announce First Quarter 2019 Financial Results on May 1, 2019
ACADIA to Host Conference Call and Webcast on Wednesday, May 1, 2019, at 4:30 p.m. Eastern Time SAN DIEGO--(BUSINESS WIRE)--Apr. 17, 2019-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will report its financial results for the first quarter ended March ... 
Printer Friendly Version
04/11/19ACADIA Pharmaceuticals Supports Parkinson’s Disease Awareness Month and World Parkinson’s Day with Local Educational Initiatives and Community Events Across the Country
SAN DIEGO--(BUSINESS WIRE)--Apr. 11, 2019-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced support of several educational events for the Parkinson’s disease community and their caregivers. ACADIA is committed to supporting the Parkinson’s community and increasing awa... 
Printer Friendly Version
04/02/19ACADIA Pharmaceuticals to Present at the 18th Annual Needham Healthcare Conference on April 9, 2019
SAN DIEGO--(BUSINESS WIRE)--Apr. 2, 2019-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the 18th Annual Needham Healthcare Conference on Tuesday, April 9, 2019 at 11:20 a.m. Eastern Time in New York City. A live webcast of ACADIA’s p... 
Printer Friendly Version
04/01/19ACADIA Pharmaceuticals Announces Promotion of Elena Ridloff, CFA to Executive Vice President, Chief Financial Officer
SAN DIEGO--(BUSINESS WIRE)--Apr. 1, 2019-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced the promotion of Elena Ridloff, CFA to Executive Vice President, Chief Financial Officer. Ms. Ridloff joined ACADIA Pharmaceuticals in April 2018 as Senior Vice President, Investor... 
Printer Friendly Version
03/27/19Positive Phase 2 Study Results of Trofinetide in Pediatric Rett Syndrome Published in Neurology, the Medical Journal of the American Academy of Neurology
-- Statistically Significant Improvement Indicates Trofinetide’s Potential for Treating Rett Syndrome -- Trofinetide for Rett Syndrome has Fast Track Status and Orphan Drug Designation in the U.S. and Orphan Drug Designation in Europe SAN DIEGO & CINCINNATI & MELBOURNE, Australia--(BUSINESS WIRE)--Mar. 27, 2019-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Neuren Pharmaceuticals Limited (ASX: NEU), and Rettsyndrome.org (RSO) announ... 
Printer Friendly Version
03/04/19ACADIA Pharmaceuticals to Present at the Cowen and Company 39th Annual Health Care Conference on March 11, 2019
SAN DIEGO--(BUSINESS WIRE)--Mar. 4, 2019-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the Cowen and Company 39th Annual Health Care Conference on Monday, March 11, 2019, at 11:20 a.m. Eastern Time in New York City. A live webcast o... 
Printer Friendly Version
02/26/19ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
- Fourth Quarter 2018 Net Sales Grew to $59.6 Million, a 37% Increase Over 4Q17 - Full Year 2018 Net Sales Grew to $223.8 Million, a 79% Increase Over Full Year 2017 - Late Stage Pipeline Progressing with Five Clinical Programs Ongoing or Commencing in 2019 - 2019 Guidance: Net Sales $275 Million to $300 Million SAN DIEGO--(BUSINESS WIRE)--Feb. 26, 2019-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biop... 
Printer Friendly Version
02/21/19ACADIA Pharmaceuticals to Present at the 8th Annual Leerink Partners Global Healthcare Conference on February 28, 2019
SAN DIEGO--(BUSINESS WIRE)--Feb. 21, 2019-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the 8th Annual Leerink Partners Global Healthcare Conference on Thursday, February 28, 2019, at 9:30 a.m. Eastern Standard Time in New York City. ... 
Printer Friendly Version
02/12/19ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results on February 26, 2019
ACADIA to Host Conference Call and Webcast on Tuesday, February 26, 2019, at 5:00 p.m. Eastern Time SAN DIEGO--(BUSINESS WIRE)--Feb. 12, 2019-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will report its financial results for the fourth quarter and ful... 
Printer Friendly Version